Chemotherapy-Induced Modulation of Rheumatoid Arthritis Activity in Oncology Patients: A Narrative Review

Ruwaidah A.R.  Abbas; Iman Sami  AbdulAmeer; Ilaf Hussain  Ali; Noor Najm  Abdullah; Osama A.  Mohsein; Shaymaa Hameed  Fayyadh

doi:10.51699/cajmns.v7i2.3130

Authors

Ruwaidah A.R. Abbas Department of Pathological Analysis, College of Applied Science, University of Fallujah, Iraq
Iman Sami AbdulAmeer University of fallujah , College of Applied Science
Ilaf Hussain Ali Middle Technical University, Community health technologies Department
Noor Najm Abdullah Department of Pathological Analyses, College of Applied Sciences, University of Fallujah, Fallujah, Iraq
Osama A. Mohsein Department of Medical Laboratory Techniques, College of Health and Medical Techniques, Northern Technical University, Kirkuk, Iraq and Thi-Qar Health Directorate, Al Habbobi Teaching Hospital, Thi-Qar, Iraq
Shaymaa Hameed Fayyadh University of fallujah , College of Applied Science

DOI:

https://doi.org/10.51699/cajmns.v7i2.3130

Keywords:

Rheumatoid arthritis, Chemotherapy, Autoimmune modulation, Inflammatory cytokines, Oncology patients

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease characterized by synovial inflammation and progressive joint destruction. In patients with concomitant malignancies, chemotherapy represents a unique immunomodulatory intervention that may significantly influence RA disease activity. This narrative review aims to summarize and critically evaluate current evidence regarding chemotherapy-induced modulation of rheumatoid arthritis activity in oncology patients. Available clinical and experimental data suggest that several chemotherapeutic agents exert profound effects on immune regulation, cytokine production, and lymphocyte proliferation, mechanisms that overlap with the immunopathogenesis of RA. Conventional cytotoxic drugs such as methotrexate, cyclophosphamide, and platinum-based agents have been reported to induce partial remission or attenuation of RA symptoms in some patients, primarily through suppression of autoreactive T and B cells. Conversely, immune checkpoint inhibitors and certain targeted therapies may exacerbate RA activity or trigger immune-related adverse events resembling inflammatory arthritis. The review highlights the dual and context-dependent nature of chemotherapy on RA, influenced by cancer type, therapeutic regimen, baseline autoimmune activity, and patient-specific immunogenetic factors. Changes in inflammatory biomarkers, including tumor necrosis factor-α, interleukin-6, and C-reactive protein, are discussed as potential indicators of chemotherapy-associated shifts in RA disease activity. Additionally, the clinical challenges of differentiating chemotherapy-related arthralgia from true RA flare are addressed. Understanding the complex interaction between chemotherapeutic agents and autoimmune pathways is essential for optimizing clinical management, minimizing adverse outcomes, and improving quality of life in oncology patients with RA. Further prospective studies are warranted to establish evidence-based guidelines for integrated oncologic and rheumatologic care.

References

Jahid, Mohd, Karim Ullah Khan, and Rafat Sultana Ahmed. "Overview of rheumatoid arthritis and scientific understanding of the disease." Mediterranean journal of rheumatology 34.3 (2023): 284-291.‏

Rose, Jonathan. "Autoimmune connective tissue diseases: systemic lupus erythematosus and rheumatoid arthritis." Emergency Medicine Clinics 40.1 (2022): 179-191.‏

Wu, Di, et al. "Systemic complications of rheumatoid arthritis: focus on pathogenesis and treatment." Frontiers in Immunology 13 (2022): 1051082.‏

Munteanu, Ioana, et al. "Co-Occurrence of Rheumatoid Arthritis and Lung Cancer—Coincidence or Not?." Life 13.10 (2023): 2089.‏

Bermas, Bonnie L., and David E. Gerber. "The Joint Problem of Rheumatoid Arthritis and Lung Cancer." Journal of Thoracic Oncology 19.2 (2024): 196-198.‏

Lopez-Olivo, Maria A., et al. "Managing Rheumatoid Arthritis in Older Adults with Cancer." Drugs & Aging (2025): 1-16.‏

Pelechas, E., et al. "AB1505 INFLAMMATORY DISEASES AND RISK OF NEOPLASIA: IS IT THE TREATMENT OR THE DISEASE IN SINE? DATA ON THE MANAGEMENT OF INFLAMMATION IN CASE OF COEXISTENCE WITH MALIGNANCY." Annals of the Rheumatic Diseases 83 (2024): 2122-2123.‏

McCarter, Kaitlin R., et al. "Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study." The Lancet Rheumatology 5.5 (2023): e274-e283.‏

Jin, Yarong, et al. "A Novel Activatable Nanoradiosensitizer for Second Near‐Infrared Fluorescence Imaging‐Guided Safe‐Dose Synergetic Chemo‐Radiotherapy of Rheumatoid Arthritis." Advanced science 11.17 (2024): 2308905.‏

Axelrad, Jordan E., Jana G. Hashash, and Steven H. Itzkowitz. "AGA clinical practice update on management of inflammatory bowel disease in patients with malignancy: commentary." Clinical Gastroenterology and Hepatology 22.7 (2024): 1365-1372.‏

Zhai, Zeqing, et al. "Attenuation of rheumatoid arthritis through the inhibition of tumor necrosis factor–induced caspase 3/gasdermin E–mediated pyroptosis." Arthritis & rheumatology 74.3 (2022): 427-440.‏

Da Silva, Rosimeire, and Tiago Casella. "Healthcare-associated infections in patients who are immunosuppressed due to chemotherapy treatment: a narrative review." The Journal of Infection in Developing Countries 16.12 (2022): 1784-1795.‏

Behranvand, Nafiseh, et al. "Chemotherapy: a double-edged sword in cancer treatment." Cancer immunology, immunotherapy 71.3 (2022): 507-526.‏

Nates, Joseph L., et al. "Septic shock in the immunocompromised cancer patient: a narrative review." Critical Care 28.1 (2024): 285.‏

Teng, Yaxin, et al. "The impact of perioperative anesthesia management-induced immunosuppression on postoperative cancer recurrence and metastasis: a narrative review." Frontiers in oncology 15 (2025): 1558652.‏

Pertsinidou, Eleftheria, et al. "In early rheumatoid arthritis, anticitrullinated peptide antibodies associate with low number of affected joints and rheumatoid factor associates with systemic inflammation." Annals of the Rheumatic Diseases 83.3 (2024): 277-287.

Ahmed, E. M., et al. "Exploring the connection between canker lesions and inflammatory cytokines: Implications for treatment and diagnosis." Regulatory Mechanisms in Biosystems 16.3 (2025): e25120-e25120.‏

Chevet, B. and Cornec, D. "Clinical presentation and treatment response in ACPA-negative rheumatoid arthritis." Joint Bone Spine, 2025.

Etani, Yuki, et al. "Distinct impact of RF and ACPA titre on the effectiveness and persistency of biologics and JAK inhibitors: The ANSWER cohort study." Modern Rheumatology (2025): roaf029.

Steiner, Guenter, et al. "Should ACR/EULAR criteria be revised changing the RF and ACPA scores?." Autoimmunity Reviews 23.1 (2024): 103421.

The adaptive immune pathway is important to RA as evidenced by the occurrence of dendritic cells, a prominent group of antigen-presenting cells, which releases a range of cytokines, HLA class II molecules

Wang, Zhandong, et al. "The mechanism of dendritic cell-T cell crosstalk in rheumatoid arthritis." Arthritis Research & Therapy 25.1 (2023): 193.‏

Al-Wakeel, M. I., et al. "The immunological markers in patients infected with typhoid fever and rheumatoid arthritis, and bacteria sensitivity." Regulatory Mechanisms in Biosystems 16.3 (2025): e25112-e25112.‏

Luo, Weihang, et al. "Distinct spatial and temporal roles for Th1, Th2, and Th17 cells in asthma." Frontiers in Immunology 13 (2022): 974066.‏

Zielinski, Christina E. "T helper cell subsets: diversification of the field." European journal of immunology 53.12 (2023): 2250218.‏

Pesce, Bárbara, et al. "TNF-α affects signature cytokines of Th1 and Th17 T cell subsets through differential actions on TNFR1 and TNFR2." International journal of molecular sciences 23.16 (2022): 9306.‏

Jang, Sunhee, Eui-Jong Kwon, and Jennifer Jooha Lee. "Rheumatoid arthritis: pathogenic roles of diverse immune cells." International journal of molecular sciences 23.2 (2022): 905.‏

Yamada, Hisakata. "Adaptive immunity in the joint of rheumatoid arthritis." Immunological Medicine 45.1 (2022): 1-11.‏

Xie, Guangyang, et al. "Age-Associated B Cells in Autoimmune Diseases: Pathogenesis and Clinical Implications." Clinical Reviews in Allergy & Immunology 68.1 (2025): 18.‏

Wen, Pengfei, and Lin Liu. "Functions of macrophages, T cells, and neutrophils in the synovial microenvironment of osteoarthritis." Journal of Inflammation Research (2025): 15671-15686.‏

Panichi, Veronica, et al. "Innate immunity and synovitis: key players in osteoarthritis progression." International Journal of Molecular Sciences 25.22 (2024): 12082.‏

Mohammed, Zahraa A., et al. "Natural Killer Cells in Multiple Sclerosis: Dual Roles in Neuroinflammation and Neuroprotection." Central Asian Journal of Medical and Natural Science 6.4 (2025): 1660-1689.‏

Khan, Shoaib, et al. "Current prospects in rheumatoid arthritis: pathophysiology, genetics, and treatments." Recent Advances in Anti-Infective Drug Discovery Formerly Recent Patents on Anti-Infective Drug Discovery 19.1 (2024): 36-55.‏

Huang, Jia-Bao, et al. "Nitric oxide synthases in rheumatoid arthritis." Molecules 28.11 (2023): 4414.‏

Song, Mong-Hsiu, et al. "Advances in Intra-Articular Injection Hydrogel Drug Delivery Systems in the Treatment of Rheumatoid Arthritis." Pharmaceutics 17.9 (2025): 1118.‏

Hoffmann, Joseph P., et al. "Sex hormone signaling and regulation of immune function." Immunity 56.11 (2023): 2472-2491.‏

Shabbir, Sania, et al. "The interplay between androgens and the immune response in polycystic ovary syndrome." Journal of Translational Medicine 21.1 (2023): 259.‏

van der Helm-van Mil, Annette H. M., and Tom W. J. Huizinga. “Advances in the Genetics of Rheumatoid Arthritis Point to Subclassification into Distinct Disease Subsets.” Arthritis Research & Therapy, vol. 10, no. 2, 2008, p. 205.

Rantapää-Dahlqvist, Solbritt, et al. “Antibodies against Cyclic Citrullinated Peptide and IgA Rheumatoid Factor Predict the Development of Rheumatoid Arthritis.” Arthritis & Rheumatism, vol. 48, no. 10, 2003, pp. 2741–2749.

Shi, Jian, et al. “Anti-Carbamylated Protein Antibodies Are Present in Arthralgia Patients and Predict the Development of Rheumatoid Arthritis.” Arthritis & Rheumatism, vol. 66, no. 2, 2014, pp. 284–293.

Willemze, Anke, et al. “The Interaction between Smoking and Shared Epitope Genes in Rheumatoid Arthritis.” Arthritis & Rheumatism, vol. 63, no. 7, 2011, pp. 1827–1836.

Gerlag, Danielle M., et al. “Prevention of Rheumatoid Arthritis: From Pathogenesis to Clinical Practice.” Nature Reviews Rheumatology, vol. 12, no. 7, 2016, pp. 374–383.

Harre, Ulf, et al. “Induction of Osteoclastogenesis and Bone Loss by Human Autoantibodies against Citrullinated Vimentin.” The Journal of Clinical Investigation, vol. 122, no. 5, 2012, pp. 1791–1802.

Dinarello, Charles A. “Proinflammatory Cytokines.” Chest, vol. 118, no. 2, 2000, pp. 503–508.

Kishimoto, Tadamitsu. “IL-6: From Its Discovery to Clinical Applications.” International Immunology, vol. 22, no. 5, 2010, pp. 347–352.

Bradley, James R. “TNF-Mediated Inflammatory Disease.” Journal of Pathology, vol. 214, no. 2, 2008, pp. 149–160.

Gregersen, Peter K., Jerome Silver, and Robert J. Winchester. “The Shared Epitope Hypothesis: An Approach to Understanding the Molecular Genetics of Susceptibility to Rheumatoid Arthritis.” Arthritis & Rheumatism, vol. 30, no. 11, 1987, pp. 1205–1213.

De Almeida, David E., et al. “The Rheumatoid Arthritis–Associated Shared Epitope Encodes a Cytokine-Like Ligand That Activates Innate Immune Signaling.” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 43, 2010, pp. 18515–18520.

Ling, Shengli, et al. “Shared Epitope–Mediated Signal Transduction via Nitric Oxide and Reactive Oxygen Species in Rheumatoid Arthritis.” Arthritis & Rheumatism, vol. 65, no. 3, 2013, pp. 558–568.

Mellor, Andrew L., and David H. Munn. “IDO Expression by Dendritic Cells: Tolerance and Treg/Th17 Balance.” Nature Reviews Immunology, vol. 4, no. 10, 2004, pp. 762–774.

Korn, Thomas, Eleni Bettelli, Mohamed Oukka, and Vijay K. Kuchroo. “IL-17 and Th17 Cells.” Annual Review of Immunology, vol. 27, 2009, pp. 485–517.

McInnes, Iain B., and Georg Schett. “The Pathogenesis of Rheumatoid Arthritis.” New England Journal of Medicine, vol. 365, no. 23, 2011, pp. 2205–2219.

Chabner, Bruce A., and Thomas G. Roberts. “Timeline: Chemotherapy and the War on Cancer.” Nature Reviews Cancer, vol. 5, no. 1, 2005, pp. 65–72.

Hanahan, Douglas, and Robert A. Weinberg. “Hallmarks of Cancer: The Next Generation.” Cell, vol. 144, no. 5, 2011, pp. 646–674.

Lateef, Diyar, Nesreen Nasser, and Osama Mohsein. "The relationships between Aplein, Vaspin and thyroid hormone levels in obese diabetic and non-diabetic women." Journal of Experimental and Clinical Medicine 41.2 (2024): 239-245.‏

Pizzo, Philip A., and David G. Poplack. “Principles of Cancer Chemotherapy.” Principles and Practice of Pediatric Oncology, 6th ed., Lippincott Williams & Wilkins, 2011, pp. 275–305.

Mackall, Crystal L., Theodore A. Fleisher, and Ronald E. Gress. “Immunodeficiency Following Chemotherapy for Cancer.” Immunological Reviews, vol. 194, 2003, pp. 152–166.

Zandvliet, Marlous L., et al. “The Impact of Chemotherapy on Immune Cell Function and Recovery.” Nature Reviews Clinical Oncology, vol. 17, no. 3, 2020, pp. 163–177.

McInnes, Iain B., and Georg Schett. “Cytokines in the Pathogenesis of Rheumatoid Arthritis.” Nature Reviews Immunology, vol. 7, no. 6, 2007, pp. 429–442.

Smolen, Josef S., Daniel Aletaha, and Iain B. McInnes. “Rheumatoid Arthritis.” The Lancet, vol. 388, no. 10055, 2016, pp. 2023–2038.

Dinarello, Charles A. “Interleukin-1 in the Pathogenesis and Treatment of Inflammatory Diseases.” Blood, vol. 117, no. 14, 2011, pp. 3720–3732.

Kishimoto, Tadamitsu. “IL-6: From Laboratory to Bedside.” Clinical Reviews in Allergy & Immunology, vol. 28, no. 3, 2005, pp. 177–186.

Gabay, Cem, and Iain Kushner. “Acute-Phase Proteins and Other Systemic Responses to Inflammation.” New England Journal of Medicine, vol. 340, no. 6, 1999, pp. 448–454.

Bracci, Lorenzo, et al. “Chemotherapy-Induced Cytokine Release and Tumor Cell Survival: Role of IL-6 and NF-κB Signaling.” Cancer Research, vol. 67, no. 9, 2007, pp. 3953–3961.

Adnan, Azher, Zainab Mohammed Farhan, and Osama A. Mohsein. "Understanding the link between diabetes mellitus and fatty liver disease: A narrative review." Int J Chem Stud 12.4 (2024): 40-48.‏

Zitvogel, Laurence, Lorenzo Galluzzi, Oliver Kepp, and Guido Kroemer. “Type I Interferons in Anticancer Immunity.” Nature Reviews Immunology, vol. 15, no. 7, 2015, pp. 405–414.

DeNardo, David G., and Lisa M. Coussens. “Inflammation and Breast Cancer: Balancing Immune Response and Tumor Progression.” Journal of Mammary Gland Biology and Neoplasia, vol. 12, no. 1, 2007, pp. 1–13.

Balkwill, Francesca. “Tumour Necrosis Factor and Cancer.” Nature Reviews Cancer, vol. 9, no. 5, 2009, pp. 361–371.

Mackall, Crystal L., Theodore A. Fleisher, and Ronald E. Gress. “Immunodeficiency Following Chemotherapy for Cancer.” Immunological Reviews, vol. 194, 2003, pp. 152–166.

Ghazi, Mustafa H., and Osama A. Mohsein. "Metabolic biomarkers in cancer: Linking metabolism to tumor progression and therapeutic targets." Central Asian Journal of Medical and Natural Science 6.1 (2025): 364-375.‏

Zandvliet, Marlous L., et al. “The Impact of Chemotherapy on Immune Cell Function and Recovery.” Nature Reviews Clinical Oncology, vol. 17, no. 3, 2020, pp. 163–177.

Richter, Michael D., et al. “Rheumatic Syndromes Associated with Cancer Immunotherapy.” Rheumatic Disease Clinics of North America, vol. 43, no. 1, 2017, pp. 65–83.

Ramos-Casals, Manuel, et al. “Autoimmune Diseases Induced by Biological Agents.” Drugs, vol. 70, no. 4, 2010, pp. 357–374.

Cappelli, Laura C., et al. “Inflammatory Arthritis and Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors.” Current Opinion in Rheumatology, vol. 30, no. 3, 2018, pp. 317–325.

Smolen, Josef S., et al. “EULAR Recommendations for the Management of Rheumatoid Arthritis.” Annals of the Rheumatic Diseases, vol. 79, no. 6, 2020, pp. 685–699.

Cronstein, Bruce N., and Thomas A. Aune. “Methotrexate and Its Mechanisms of Action in Inflammatory Arthritis.” Nature Reviews Rheumatology, vol. 16, no. 3, 2020, pp. 145–154.

Wessels, Jamal A. M., et al. “Efficacy and Toxicity of Methotrexate in Rheumatoid Arthritis.” Arthritis & Rheumatism, vol. 54, no. 4, 2006, pp. 1087–1093.

Bongartz, Tim, et al. “Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections.” JAMA, vol. 295, no. 19, 2006, pp. 2275–2285.

Listing, Joachim, et al. “Mortality in Rheumatoid Arthritis Patients Treated with Biologic Agents.” Annals of the Rheumatic Diseases, vol. 74, no. 6, 2015, pp. 1072–1079.

Smolen, Josef S., et al. “Targeted Synthetic DMARDs in Rheumatoid Arthritis.” Lancet, vol. 388, no. 10055, 2016, pp. 2023–2038.

Mohammad, Sarmad, Abdullah Mohsen, and Idriss Jalil. "Assessing the prevalence of bacterial vaginosis among infertile women in Thi-Qar Province, Iraq." Infection Epidemiology and Microbiology 10.4 (2024): 0-0.‏

Furer, Victoria, et al. “2019 Update of EULAR Recommendations for Vaccination in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases.” Annals of the Rheumatic Diseases, vol. 79, no. 1, 2020, pp. 39–52.

Visser, Karin, and Ferdinand C. Breedveld. “Monitoring of DMARD Therapy in Rheumatoid Arthritis.” Best Practice & Research Clinical Rheumatology, vol. 21, no. 5, 2007, pp. 859–873.

Loprinzi, Charles L., et al. “Chemotherapy-Induced Arthralgia and Myalgia.” Journal of Clinical Oncology, vol. 22, no. 14, 2004, pp. 2959–2967.

Faqri, Ayoob Murtadha Alshaikh, et al. "The role of cytokines in autoimmune diseases: pathogenesis and therapeutic implications." Central Asian Journal of Medical and Natural Science 6.3 (2025): 852-873.‏

Henry, N. Lynn, et al. “Management of Musculoskeletal Symptoms Associated with Cancer Therapy.” Journal of Clinical Oncology, vol. 30, no. 18, 2012, pp. 2333–2340.

Cush, John J. “Early Rheumatoid Arthritis: Is There a Window of Opportunity?” Journal of Rheumatology, vol. 34, no. 1, 2007, pp. 1–7.

Ramos-Casals, Manuel, et al. “Drug-Induced Autoimmune Diseases.” Current Opinion in Rheumatology, vol. 20, no. 1, 2008, pp. 56–64.

Smolen, Josef S., et al. “Treating Rheumatoid Arthritis to Target.” Annals of the Rheumatic Diseases, vol. 69, no. 4, 2010, pp. 631–637